Wedbush Downgrades TCR2 Therapeutics (TCRR) to Neutral, Following Clinical Business Update
Tweet
Share
E-mailGet Alerts TCRR Hot Sheet
Price: $1.48 --0%
Rating Summary:
3 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush analyst David Nierengarten downgraded TCR2 Therapeutics (NASDAQ: TCRR) from Outperform to Neutral with a price target of $11.00 (from $45.00).
For an analyst ratings summary and ratings history on TCR2 Therapeutics click here. For more ratings news on TCR2 Therapeutics click here.
Shares of TCR2 Therapeutics closed at $15.72 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Wedbush Downgrades Globant S.A. (GLOB) to Neutral on balanced risk/reward
- DA Davidson Downgrades Blaize Inc. (BZAI) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
